Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo: Laboratory investigation

Journal of Neurosurgery

Volumn 114, Issue 3, 2011, Pages 689-694

  Wang, Weijun ^a   Ghandi, Alex ^c   Liebes, Leonard ^c   Louie, Stan G ^a   Hofman, Florence M ^a   Schönthal, Axel H ^b   Chen, Thomas C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Carboxylesterase; CPT 11; Glioma; Intratumoral delivery; Irinotecan; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY TEST; DEATH; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TRANSFORMATION; EXPERIMENTAL STUDY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GLIOMA; HUMANS; MICE; MICE, NUDE; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

EID: 79952270955     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2010.2.JNS09719     Document Type: Article

References (24)

1. Ando Y, Hasegawa Y: Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 37:565-574, 2005 (Pubitemid 41434162)
2. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926, 2000 (Pubitemid 32059164)
3. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410, 2003 (Pubitemid 37328844)
4. Chen TC, Su S, Fry D, Liebes L: Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 97 (9 Suppl):2363-2373, 2003 (Pubitemid 36444047)
5. Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B, et al: Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol 64:893-899, 2009
6. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004 (Pubitemid 41103619)
7. Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR: Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 24:353-367, 2001 (Pubitemid 32417534)
8. Kaneda N, Hosokawa Y, Yokokura T, Awazu S: Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats. Biol Pharm Bull 20:992-996, 1997 (Pubitemid 27432874)
9. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991
10. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, et al: Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 9:393-403, 2007
11. Kuhn JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Williston Park) 16 (8 Suppl 7):33-40, 2002
12. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y: Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124:2505-2511, 2009
13. Kweekel D, Guchelaar HJ, Gelderblom H: Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34:656-669, 2008
14. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, et al: Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 66:2801-2806, 2006
15. Perucca E: Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246-255, 2006
16. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, et al: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8:189-193, 2006 (Pubitemid 46542664)
17. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, et al: Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer 115:2964-2970, 2009
18. Rivory LP: Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci 922:205-215, 2000
19. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, et al: Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol 92:165-175, 2009
20. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, et al: Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020, 2000 (Pubitemid 30305100)
21. Verschraegen CF, Jaeckle K, Giovanella B, Knight V, Gilbert BE: Alternative administration of camptothecin analogues. Ann N Y Acad Sci 922:237-246, 2000 (Pubitemid 32050257)
22. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS: Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol 11:80-91, 2009
23. Xu G, Zhang W, Ma MK, McLeod HL: Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611, 2002 (Pubitemid 34856347)
24. Zhang W, Xu G, McLeod HL: Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. Appl Immunohistochem Mol Morphol 10:374-380, 2002 (Pubitemid 35453699)